Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an intravenous solution for injection use. It enhances cardiac contractility by sensitizing troponin C to calcium and induces vasodilation by opening ATP‑sensitive potassium channels, making it suitable for patients with acute decompensated heart failure and related low‑output states.

GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levosimendan is used in the management of heart failure syndromes where cardiac output is compromised.

- Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Low cardiac output syndrome: enhances contractility to support systemic perfusion. - Cardiogenic shock (off‑label): provides inotropic support when conventional agents are insufficient.

Levosimendan may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Hypotension: transient drop in blood pressure. - Tachycardia: increased heart rate. - Flushing: warmth and reddening of skin.

Serious or Rare Side Effects: - Arrhythmias: ventricular or atrial ectopic beats. - Severe hypotension: refractory low blood pressure. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis.

When using Levosimendan, clinicians should consider several precautionary measures to ensure patient safety.

- Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Blood pressure monitoring: watch for significant hypotension, especially in patients on vasodilators. - Electrolyte balance: correct hypokalemia and hypomagnesemia before administration. - Concomitant inotropes: avoid simultaneous use with other potent inotropes unless clinically justified. - Renal or hepatic impairment: adjust infusion rate and monitor organ function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Calcium channel blockers (e.g., diltiazem): can enhance negative inotropic effects. - Beta‑blockers: may blunt desired inotropic response.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances. - Anticoagulants: monitor for bleeding if hypotension occurs. - Other inotropes (e.g., dobutamine): assess additive cardiac effects.